The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
To understand PNC-28 you must understand why MDM2 makes cancer cells vulnerable to a peptide that normal cells do not respond to. The selectivity mechanism is the most elegant aspect of this compound's pharmacology.
p53 (encoded by TP53) is the most frequently mutated gene in human cancer — mutated or functionally inactivated in over 50% of all cancers. Its proper name, 'guardian of the genome,' reflects its role: p53 detects DNA damage, arrested replication, oncogenic stress, and hypoxia, then drives the cell into apoptosis or permanent cell cycle arrest to prevent damaged cells from proliferating. In normal cells, p53 activity is tightly regulated by MDM2 (murine double minute 2; human homolog hdm2), an E3 ubiquitin ligase that binds p53's N-terminal transactivation domain (amino acids 17-26 — the sequence PNC-28 is derived from) and polyubiquitinates p53 for proteasomal degradation. MDM2 is p53's primary negative regulator; they form a feedback loop (p53 transcribes MDM2; MDM2 degrades p53).
In cancer: MDM2 is frequently overexpressed, either through MDM2 gene amplification (particularly in liposarcomas, osteosarcomas) or through transcriptional upregulation. In cancer cells, MDM2 not only accumulates in the nucleus and cytoplasm (suppressing p53) but also, critically, is expressed on the plasma membrane surface. Normal cells do not express MDM2 on their extracellular surface. This plasma membrane MDM2 expression by cancer cells is the selectivity handle that PNC-28 exploits.
THE CENTRAL TENSION
PNC-28 inverts the standard Peptide Bible cancer calculus. Every other chapter warns against using its compound in cancer patients because GH, IGF-1, angiogenesis, or cell proliferation signals could feed tumor growth. PNC-28 was designed to exploit a cancer-specific surface marker (plasma membrane MDM2) to deliver a lethal pore-forming signal selectively to tumor cells. The in vitro human cancer cell data is compelling — necrosis of 20+ cancer cell lines, pore formation confirmed ultrastructurally. The in vivo mouse data shows tumor growth inhibition. What does not exist is a published human Phase 3 trial. The community using PNC-28 for general health without active cancer is using an anti-cancer peptide in a population where its primary mechanism has no pharmacological target (no plasma membrane MDM2 to bind).
Feature
PNC-27
PNC-28
p53 domain
AA12-26 (15 amino acids)
AA17-26 (10 amino acids)
Full sequence
p53 AA12-26 + penetratin
p53 AA17-26 + penetratin
Relative literature
More papers; earlier characterized; broader cancer line testing
Specifically tested in pancreatic cancer in vivo; highly metastatic cell destruction
Selectivity mechanism
Same: plasma membrane MDM2 binding
Same: plasma membrane MDM2 binding
Anti-cancer mechanism
Same: pore formation, necrosis
Same: pore formation, necrosis
Key difference
Longer p53 domain; may have slightly different MDM2 binding kinetics
Shorter p53 domain; PNC-28 particularly noted for destroying highly metastatic cancer cells
In vivo evidence
Mouse models (multiple)
Pincus 2006 (pancreatic xenograft)
Community availability
Xcells, research vendors
Xcells, research vendors
p53 amino acids 17-26 (TFSDLWKLL) constitute the MDM2 contact interface of p53's transactivation domain. When p53 is functioning normally, this sequence is buried intracellularly and unavailable for surface binding. In PNC-28, this sequence is presented as a free synthetic peptide with the penetratin sequence attached. The TFSDLWKLL sequence has high affinity for MDM2's hydrophobic binding groove, the same groove that normal p53 occupies. When PNC-28 encounters MDM2 expressed on the outer surface of a cancer cell membrane, the TFSDLWKLL domain binds with high specificity to the exposed MDM2 groove.
Penetratin (RQIKIWFQNRRMKWKK) is a 16-amino acid cell-penetrating peptide derived from the Drosophila Antennapedia homeodomain. It was one of the first characterized cell-penetrating peptides and is known to insert into lipid bilayers and traverse cell membranes. In PNC-27/28, penetratin serves the dual function of membrane insertion and membrane residence — anchoring the peptide in the lipid bilayer after it binds MDM2 on the cancer cell surface.
After PNC-28 binds MDM2 on the cancer cell surface via its p53-domain and inserts into the membrane via penetratin: multiple PNC-28 molecules oligomerize around the membrane-anchored MDM2, forming ring-shaped MDM2-PNC structures ultrastructurally similar to those produced by Streptolysin-O, a well-characterized pore-forming bacterial toxin. These structures become transmembrane pores. The result: direct membrane disruption; loss of ionic homeostasis; rapid necrosis (not apoptosis) of the cancer cell within minutes to hours. The selectivity: normal cells without plasma membrane MDM2 cannot anchor PNC-28 to the membrane surface; without the MDM2 anchor, PNC-28 cannot oligomerize and cannot form pores in normal cell membranes.
Domain
Sequence
Function
Target
p53 MDM2-binding domain
TFSDLWKLL (p53 AA 17-26)
Binds MDM2 protein expressed on cancer cell plasma membrane with high specificity
Plasma membrane MDM2 (hdm2) expressed selectively on cancer cells
Penetratin
RQIKIWFQNRRMKWKK (Antennapedia homeodomain)
Membrane insertion; lipid bilayer residence; delivers p53 domain to membrane surface
Lipid bilayer of the cell membrane
Combined action
TFSDLWKLL-penetratin chimera = PNC-28
MDM2 binding → membrane anchoring → oligomerization → pore formation
Cancer cell plasma membrane MDM2 → transmembrane pore → necrosis
The most extensive PNC-28 evidence is from human cancer cell lines. Key findings across multiple papers from the Pincus and Brandt-Rauf groups at SUNY Downstate: PNC-28 and PNC-27 induce necrosis within minutes to hours in 20+ human epithelial cancer cell lines tested, including pancreatic cancer, colon cancer, lung cancer, breast cancer, ovarian cancer, endometrial cancer, and leukemia cell lines. Pore formation was confirmed by ultrastructural studies: immunogold electron microscopy showed co-localization of PNC peptides with MDM2 in ring-shaped structures on cancer cell membranes, structurally similar to Streptolysin-O pores. Normal cells treated with PNC-27 showed no membrane disruption and no toxicity. A control peptide (PNC-29, same penetratin sequence, scrambled p53 domain) did not produce pore formation or cancer cell death, confirming that the MDM2-binding specificity of the p53 domain is required. Grade D: in vitro; human cancer cell lines; mechanistically compelling; requires human clinical trial validation.
Pincus MR, et al. (2006). PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. International Journal of Cancer. 119(7):1577-1585. Design: mouse xenograft model; human pancreatic cancer cells implanted in immunocompromised mice; PNC-28 treatment via local injection. Results: significant tumor growth inhibition; tumor regression in treated mice vs continued growth in controls; no apparent toxicity to normal tissues at effective anti-tumor doses. This is the primary in vivo evidence for PNC-28 specifically (as opposed to PNC-27 which has additional animal data). Grade C: mouse xenograft; human cancer cells in immunocompromised animals; relevant model but not clinical.
AACR 2011 abstract: PNC-27 ex vivo cytotoxicity on primary human ovarian and endometrial cancer samples; cancer cells killed; non-cancerous stromal cells spared. This ex vivo human primary tissue data is pharmacologically more relevant than cell line data (primary tumor cells vs established cell lines) but is not a clinical trial. Grade D-C (ex vivo primary human tissue; not a controlled clinical trial).
Evidence
Grade
Finding
Limitation
In vitro: 20+ human cancer cell lines (AACR 2008; Pincus lab)
D (in vitro human cells)
Pore formation in all tested cancer lines; no toxicity in normal cells; ultrastructural confirmation of MDM2-PNC co-localization
Cell lines vs primary tumor; no clinical endpoint; no systemic pharmacokinetics
PNC-28 in vivo mouse pancreatic cancer (Pincus 2006, Int J Cancer)
C (mouse xenograft)
Tumor growth inhibition; tumor regression; no apparent normal tissue toxicity
Immunocompromised mouse; xenograft (not syngeneic); not clinical
Ex vivo primary human ovarian/endometrial cancer (AACR 2011)
D-C (ex vivo primary human)
Primary human cancer cells killed; stromal cells spared; confirms selectivity in primary tumor architecture
Ex vivo; not systemic; not Phase 1/2/3 clinical trial
Human clinical trial for PNC-28 specifically
Not confirmed
No published Phase 1/2/3 trial for PNC-28 as a standalone clinical agent in humans identified in available literature as of mid-2026
This is the critical evidence gap
This is the only compound in The Peptide Bible where an individual with active cancer considering this compound is in the designed-use context, not the contraindicated context.
Standard Peptide Bible chapter structure: the Active Malignancy section warns against using compounds that elevate GH, IGF-1, angiogenic factors, or cell proliferation signals that could theoretically feed tumor growth. PNC-28 is categorically different. It was designed by p53 researchers specifically as an anti-cancer peptide. The MDM2 target is expressed on cancer cells. The pore-forming mechanism kills cancer cells. Using PNC-28 in a person with active cancer aligns with the compound's designed pharmacology.
ACTIVE MALIGNANCY: PHYSICIAN OVERSIGHT MANDATORY — NOT BECAUSE CONTRAINDICATED
Anyone with active cancer considering PNC-28 should involve their oncologist not because PNC-28 is contraindicated in cancer but because: (1) cancer treatment is complex; interactions with chemotherapy, radiation, checkpoint inhibitors, and other oncological treatments are unstudied; (2) PNC-28 is an experimental research compound without an approved indication; (3) tumor cell lysis (necrosis) at scale can produce a tumor lysis syndrome-like inflammatory response; (4) the oncological context determines which tumors are most MDM2-surface-expressing and thus most likely to respond. Self-directed cancer treatment is not appropriate regardless of the compound's mechanism.
Community users accessing PNC-28 through Xcells for general 'cellular health,' 'p53 pathway optimization,' or generalized anti-cancer prevention are using a compound whose primary mechanism requires plasma membrane MDM2 as the anchor. Normal healthy cells do not express MDM2 on their surface. In the absence of cancer cells expressing surface MDM2, PNC-28 has no primary pharmacological target in the body. The 'p53 activation' framing seen in community discussions is mechanistically incorrect: PNC-28 does not activate nuclear p53 transcription or restore p53 tumor suppressor function. It presents a p53-derived sequence to kill cells that have already lost p53 regulation and express surface MDM2 as a consequence.
PNC-28 is a chimeric peptide containing two distinct domains: p53 AA17-26 (TFSDLWKLL) and penetratin (RQIKIWFQNRRMKWKK). The full peptide sequence and MW require HPLC purity verification (≥98%) and mass spectrometric identity confirmation. Penetratin contains multiple arginine and lysine residues (highly positive charge) that create reconstitution and aggregation challenges. Community suppliers (Xcells) list PNC-28; verify independent third-party testing certificates before use. Storage: lyophilized; refrigerate; reconstitute in sterile water or appropriate peptide solvent. Do not reconstitute in acidic buffers that could affect the basic penetratin domain's solubility. Route: SubQ injection is the primary community route; IV or intratumoral routes were used in some research contexts.
This is mechanistically incorrect and is the most common mischaracterization in community discussion. PNC-28 does not restore nuclear p53 activity; it does not prevent MDM2 from ubiquitinating intracellular p53; it does not upregulate p53 target genes. It presents the p53 MDM2-binding domain externally on the cell surface, where it binds plasma membrane MDM2 on cancer cells and initiates pore formation. The mechanism is membrane disruption and tumor cell necrosis, not p53 transcriptional activation. These are completely different pharmacological actions.
Cancer prevention requires interaction with biological processes that precede cancer cell formation. PNC-28's mechanism requires plasma membrane MDM2, which is expressed on cancer cells, not on normal precancerous cells or healthy tissue. Pre-cancer cells (dysplastic cells with early mutations but without full malignant transformation) may or may not express surface MDM2 at levels sufficient for PNC-28 interaction. The compound was not developed or tested for cancer prevention; it was developed for treatment of established cancer with surface MDM2 expression.
In vitro selectivity (cancer cells killed; normal cells spared at the same concentrations) is a pharmacological property in controlled cell culture conditions. Systemic administration in vivo introduces pharmacokinetic variables: distribution to normal tissues, peptide stability, penetratin-mediated membrane interactions in unexpected cell types at high peptide concentrations, and immune reactions to a chimeric foreign peptide sequence. The in vitro selectivity is real and mechanistically explained; systemic safety in human non-cancer subjects at community dosing frequencies is not established.
Pincus MR, Fenelus M, Michl J, et al. (2006). PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. International Journal of Cancer. 119(7):1577-1585. [Primary in vivo PNC-28 evidence; pancreatic cancer mouse xenograft; tumor growth inhibition; the most important single PNC-28 paper.]
Pincus MR, et al. (2008). The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Annals of Surgical Oncology. 15(12):3588-3600. [Mechanism characterization; penetratin drives necrosis (not apoptosis); pore formation mechanism; human pancreatic cancer cells.]
AACR 2008 abstract (Kanovsky, Pincus et al.). PNC-27 and PNC-28 anticancer peptides selectively kill cancer cells by pore formation dependent on binding to hdm2 in cancer cell membranes. Cancer Research. 68(9 Suppl):LB-195. [Ultrastructural pore formation confirmation; MDM2 co-localization; ring-shaped structures similar to Streptolysin-O; 20+ cancer cell lines; normal cell sparing.]
AACR 2011 abstract. Ex vivo cytotoxicity of PNC-27 on primary human ovarian and endometrial cancers. Cancer Research. 71(18 Suppl):C44. [Ex vivo primary human cancer tissue; cancer cells killed; stromal cells spared; extends from cell lines to primary human tumor architecture.]
Do TN, Rosal RV, Drew L, et al. (2003). Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene. 22(9):1431-1444. [Foundational paper; p53 MDM2-binding domain peptide induces necrosis preferentially in cancer cells; precursor to PNC designation.]
Wang H, Yan C, Asber AC, Yao L, Brandt-Rauf PW, Pincus MR. (2004). NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry. 43(7):1854-1861. [Structural characterization of the p53 MDM2-binding domain peptide; NMR solution structure; basis for the PNC peptide design.]
PNC-28 is the most mechanistically specific anti-cancer peptide in this book: it targets a cancer cell surface marker, kills via pore formation, and spares normal cells in vitro by the same mechanism. It is also the compound where community off-label use is the most pharmacologically disconnected from the evidence context.
The compound's story resolves clearly: the Pincus and Brandt-Rauf groups at SUNY Downstate developed PNC-28 from a rigorous understanding of the p53-MDM2 interaction, exploiting the specific cell surface MDM2 expression of cancer cells to create a tumor-selective membrane disruptor. The in vitro data across 20+ cancer cell lines is compelling; the in vivo mouse data supports clinical development; the ex vivo human primary tissue data extends the selectivity finding beyond cell lines. What has not followed is an accessible published human Phase 1/2/3 trial for this specific compound. The community using it for general health has no pharmacological target for its primary mechanism. The community using it as a cancer adjunct is in the compound's designed context but requires oncological oversight.
— End of PNC-28 — End of The Peptide Bible Chapters —
THE PEPTIDE BIBLE | PNC-28 | For Research & Educational Purposes Only
PNC-28: chimeric anti-cancer peptide. Domain 1: p53 AA17-26 (TFSDLWKLL; MDM2-binding sequence from p53 transactivation domain). Domain 2: Penetratin (RQIKIWFQNRRMKWKK; Antennapedia homeodomain cell-penetrating sequence). Developed by Pincus, Brandt-Rauf et al., SUNY Downstate Medical Center. NOT FDA-approved. No published human Phase 1/2/3 RCT confirmed. Xcells carries it. MECHANISM: MDM2 (hdm2) is constitutively expressed on cancer cell plasma membranes but NOT on normal cell surfaces → PNC-28 p53 domain binds surface MDM2 on cancer cells → penetratin inserts peptide into cancer cell membrane → multiple PNC-28 molecules oligomerize around membrane-anchored MDM2 → form transmembrane pores (ultrastructurally similar to Streptolysin-O pores) → direct cell lysis/necrosis within minutes to hours. SELECTIVITY: normal cells lack plasma membrane MDM2 → no PNC-28 anchoring → no pore formation → no toxicity. EVIDENCE: in vitro (Grade D): 20+ human cancer cell lines (pancreatic, colon, lung, breast, ovarian, leukemia, endometrial); pore formation confirmed ultrastructurally; normal cell sparing confirmed; control peptide PNC-29 (scrambled p53 domain) inactive (confirms MDM2-binding specificity required). In vivo (Grade C): Pincus 2006 (Int J Cancer); pancreatic cancer mouse xenograft; tumor growth inhibition. Ex vivo (Grade D-C): AACR 2011; primary human ovarian/endometrial cancer; cancer cell death; stromal sparing. PNC-27 vs PNC-28: PNC-27 = p53 AA12-26 (longer); PNC-28 = p53 AA17-26 (shorter); same mechanism; PNC-28 particularly noted for highly metastatic cell destruction. THE REVERSAL: unlike every other Bible chapter, active malignancy = DESIGNED USE CONTEXT, not contraindication. Physician oversight mandatory in cancer context (not because contraindicated but because experimental oncological compound). COMMUNITY OFF-LABEL (general health): no pharmacological target in cancer-free individuals (no surface MDM2); 'p53 activation' framing is mechanistically incorrect; primary mechanism inactive without surface MDM2. MDM2 BIOLOGY: MDM2 = E3 ubiquitin ligase; primary p53 negative regulator; frequently overexpressed in cancer; cancer cells express MDM2 on plasma membrane surface (normal cells do not). SOURCING: HPLC ≥98%; mass spec identity; avoid acidic reconstitution buffers; refrigerate lyophilized.
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.
Engineered to Not Be EPO. Proven to Regenerate Nerves in Humans. WADA Banned Anyway. And the Company That Made It No Longer Exists.